Contineum Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Contineum Therapeutics, a clinical-stage biopharmaceutical company, is seeking to raise approximately $150 million through an initial public offering to advance its pipeline of therapies for neuroscience, inflammation, and immunology indications.
NASDAQ
Contineum Therapeutics, a clinical-stage biopharmaceutical company, has filed for an initial public offering to further its development of oral small molecule therapies for neuroscience, inflammation, and immunology indications.